Published in Neurology on June 01, 1992
Computer-Based Balance Training for People With Parkinson's Disease | NCT01162226
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry (2002) 2.48
Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology (2014) 2.44
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol (2009) 2.29
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord (2005) 2.19
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology (2014) 2.15
Pesticides and Parkinson's disease--is there a link? Environ Health Perspect (2006) 2.01
Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet (2002) 1.93
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol (2011) 1.90
Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med (2008) 1.90
Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain (2009) 1.77
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med (2012) 1.75
Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage (2008) 1.74
Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology (2011) 1.68
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry (1995) 1.65
Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ (2008) 1.42
Cognitive rehabiliation for Parkinson's disease demantia: a study protocol for a pilot randomised controlled trial. Trials (2016) 1.42
Epidemiology of Parkinson's disease. J Neurol (2008) 1.38
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One (2012) 1.33
Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry (2006) 1.31
Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol (2009) 1.29
The supplementary motor area contributes to the timing of the anticipatory postural adjustment during step initiation in participants with and without Parkinson's disease. Neuroscience (2009) 1.27
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet (2005) 1.24
Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord (2010) 1.23
Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet (2003) 1.20
How far are we in understanding the cause of Parkinson's disease? J Neurol Neurosurg Psychiatry (1996) 1.20
Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology (2012) 1.17
Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology (2012) 1.17
Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.14
What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry (2000) 1.14
Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology (2015) 1.13
Approach to diagnosis of Parkinson disease. Can Fam Physician (2006) 1.13
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Statin use and the risk of Parkinson disease. Neurology (2008) 1.10
Impairment of vowel articulation as a possible marker of disease progression in Parkinson's disease. PLoS One (2012) 1.10
Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. Am J Epidemiol (2009) 1.08
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain (2012) 1.08
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease. Mov Disord (2006) 1.07
Can stooped posture explain multidirectional postural instability in patients with Parkinson's disease? Exp Brain Res (2005) 1.06
ATP13A2 variability in Parkinson disease. Hum Mutat (2009) 1.05
Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet (2010) 1.03
Idiopathic Parkinson's disease: epidemiology, diagnosis and management. Br J Gen Pract (1995) 1.03
Apathy and depression: separate factors in Parkinson's disease. J Int Neuropsychol Soc (2011) 1.02
Arm swing magnitude and asymmetry during gait in the early stages of Parkinson's disease. Gait Posture (2009) 1.01
Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One (2013) 1.00
Validation of hospital register-based diagnosis of Parkinson's disease. Dan Med J (2012) 0.98
PINK1 mutations and parkinsonism. Neurology (2008) 0.98
Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res (2006) 0.98
Effect of subthalamic stimulation on voice and speech in Parkinson's disease: for the better or worse? Front Neurol (2014) 0.98
Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 0.98
Movement disorders after stroke in adults: a review. Tremor Other Hyperkinet Mov (N Y) (2012) 0.97
Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord (2009) 0.97
Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother (2012) 0.96
Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach. PLoS One (2013) 0.95
Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One (2013) 0.95
Predictors of mild cognitive impairment in early-stage Parkinson's disease. Dement Geriatr Cogn Dis Extra (2013) 0.95
Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem (2009) 0.95
Scoliosis in patients with Parkinson's disease. J Clin Neurol (2009) 0.94
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology (2015) 0.93
The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol (2014) 0.93
Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J Exp Med (2005) 0.93
Effects of STN DBS on rigidity in Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng (2007) 0.92
Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology (2013) 0.92
Distinguishing the central drive to tremor in Parkinson's disease and essential tremor. J Neurosci (2015) 0.91
Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord (2010) 0.91
Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients. J Neural Transm (Vienna) (1997) 0.90
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology (2014) 0.88
Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environ Int (2013) 0.88
Aberrant sexual behaviours in Parkinson's disease during dopaminergic treatment. J Neurol (2007) 0.88
Risk of falls in Parkinson's disease: a cross-sectional study of 160 patients. Parkinsons Dis (2012) 0.88
Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS One (2014) 0.88
Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. Parkinsonism Relat Disord (2010) 0.88
Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neurosci Lett (2009) 0.87
Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int (2013) 0.87
Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes. Neuroimage Clin (2013) 0.87
Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases. Front Genet (2014) 0.86
Glutathione S-transferase mu, omega, pi, and theta class variants and smoking in Parkinson's disease. Neurosci Lett (2006) 0.86
Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One (2011) 0.86
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord (2014) 0.86
Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease. Mech Ageing Dev (2010) 0.85
Function of basal ganglia in bridging cognitive and motor modules to perform an action. Front Neurosci (2014) 0.85
Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord (2011) 0.85
The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis (2013) 0.85
Cerebral magnetic resonance elastography in supranuclear palsy and idiopathic Parkinson's disease. Neuroimage Clin (2013) 0.85
Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts. PLoS One (2012) 0.85
Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease. Environ Res (2013) 0.85
Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS One (2011) 0.85
Parkinson's disease. Diagnosis and treatment. West J Med (1996) 0.84
The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry (2002) 0.84
Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience (2014) 0.83
Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm (Vienna) (2008) 0.83
Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson's disease. Clin Res Cardiol (2010) 0.83
Functional Aspects of Gait in Essential Tremor: A Comparison with Age-Matched Parkinson's Disease Cases, Dystonia Cases, and Controls. Tremor Other Hyperkinet Mov (N Y) (2015) 0.83
Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci (2009) 0.82
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Social deprivation and premature mortality: regional comparison across England. BMJ (1993) 9.74
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Life course epidemiology. J Epidemiol Community Health (2003) 6.75
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet (1999) 3.94
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Counting the cost of social disadvantage in primary care: retrospective analysis of patient data. BMJ (1997) 2.82
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain (1994) 2.77
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord (1997) 2.61
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry (2002) 2.48
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Streptococcal infection, Tourette syndrome, and OCD: is there a connection? Neurology (2009) 2.33
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1979) 2.20
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ (2000) 2.17
Equity in the NHS. Monitoring and promoting equity in primary and secondary care. BMJ (1994) 2.13
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain (2006) 2.07
Low-dose olanzapine for levodopa induced dyskinesias. Neurology (2000) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry (1989) 1.95
Lay diagnosis and health-care-seeking behaviour for chest pain in south Asians and Europeans. Lancet (1997) 1.94
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 1.83
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol (1989) 1.79
Commentary: socioeconomic position should be measured accurately. BMJ (1999) 1.79
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol (1995) 1.79
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology (2005) 1.77
Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord (1998) 1.74
A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry (1984) 1.72
Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res (1998) 1.71
Neurological deterioration in young adults with phenylketonuria. Lancet (1990) 1.71
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker. BMJ (1997) 1.67
The impact of childhood body mass index on timing of puberty, adult stature and obesity: a follow-up study based on adolescent anthropometry recorded at Christ's Hospital (1936-1964). Int J Obes (Lond) (2006) 1.67
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem (1990) 1.66
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology (2001) 1.64
Birth size and arterial compliance in young adults. Lancet (2000) 1.63
Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology (2003) 1.61
From the surgery to the surgeon: does deprivation influence consultation and operation rates? Br J Gen Pract (1995) 1.57
New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology (1991) 1.57
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Tau gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry (2004) 1.56
The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55
Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 1.54
Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet (1980) 1.51
Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience (2005) 1.51
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry (2003) 1.51
Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1990) 1.50
Incidental Lewy body disease in black Africans. Lancet (1994) 1.50
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol (1992) 1.49
Chronic basal meningitis and vasculitis in acquired immunodeficiency syndrome. A possible role for human immunodeficiency virus. Arch Pathol Lab Med (1989) 1.49